A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
出版年份 2013 全文链接
标题
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
作者
关键词
Ganetespib, Hsp90 inhibitor, Pharmacokinetics, Phase I study, Solid tumors
出版物
BMC CANCER
Volume 13, Issue 1, Pages -
出版商
Springer Nature
发表日期
2013-03-26
DOI
10.1186/1471-2407-13-152
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
- (2012) L. Neckers et al. CLINICAL CANCER RESEARCH
- Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
- (2012) David A. Proia et al. INVESTIGATIONAL NEW DRUGS
- The network interaction of the human cytosolic 90kDa heat shock protein Hsp90: A target for cancer therapeutics
- (2012) Viviane C.H. da Silva et al. Journal of Proteomics
- Abstract C212: A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats.
- (2012) D. Zhou et al. MOLECULAR CANCER THERAPEUTICS
- HSP90 as a platform for the assembly of more effective cancer chemotherapy
- (2011) Luke Whitesell et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
- (2011) A. Rajan et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors
- (2011) Simon Pacey et al. CLINICAL CANCER RESEARCH
- Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010
- (2011) Samir Messaoudi et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
- (2011) W. Ying et al. MOLECULAR CANCER THERAPEUTICS
- Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
- (2011) David A. Proia et al. PLoS One
- An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors
- (2010) Naveen Dakappagari et al. BIOMARKERS
- Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells
- (2010) Wen-Chuan Wu et al. EXPERIMENTAL EYE RESEARCH
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors
- (2010) Ramesh K. Ramanathan et al. JOURNAL OF CLINICAL ONCOLOGY
- EGF signaling activates proliferation and blocks apoptosis of mouse and human intestinal stem/progenitor cells in long-term monolayer cell culture
- (2010) Atsushi Suzuki et al. LABORATORY INVESTIGATION
- Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
- (2010) J E Lancet et al. LEUKEMIA
- Geldanamycin inhibits TGF-β signaling through induction of Hsp70
- (2009) Chang-Hyun Yun et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Hsp90 and co-chaperones twist the functions of diverse client proteins
- (2009) Abbey Zuehlke et al. BIOPOLYMERS
- Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation
- (2008) B. Dewaele et al. CLINICAL CANCER RESEARCH
- Radicicol but not geldanamycin evokes oxidative stress response and efflux protein inhibition in ARPE-19 human retinal pigment epithelial cells
- (2008) Tuomas Ryhänen et al. EUROPEAN JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now